Information
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative
Original sourceAI Summary
PROCEPT BioRobotics reported Q4 2025 revenue of $76.4 million, achieving a 12% year-over-year growth. While the procedure volume surged by 69%, a net loss increased to $29.8 million, raising concerns about long-term profitability despite optimistic revenue guidance for 2026 of $390-410 million.
Sentiment Rationale
While revenue growth is strong, increased net losses raise concerns about profitability. Historical reactions show mixed market responses in similar scenarios.
Trading Thesis
PRCT aims for growth; monitor performance against guidance in 2026 for investment opportunities.
Market-Moving
- Investors should watch for any changes in procedure volumes in Q1 2026.
- Price sensitivity due to adjusted handpiece pricing may impact future revenue.
- Management's execution of cost control and revenue growth strategy is crucial.
- Potential regulatory developments regarding robotic surgery could affect market sentiment.
Key Facts
- PRCT reported Q4 2025 revenue of $76.4 million, up 12% year-over-year.
- Procedure volume reached 12,200, a 69% increase from last year.
- Cost management led to a higher handpiece selling price by 5% to $3,340.
- 2026 revenue guidance set at $390-$410 million, reflecting growth of 27%-33%.
- Net loss for Q4 was $29.8 million, up from $18.9 million year-over-year.
Companies Mentioned
- Intuitive Surgical, Inc. (ISRG): Key competitor in the robotic surgical space; impact can ripple through robotics sector.
- Medtronic plc (MDT): Major player; competition in surgical devices could affect PRCT's market growth.
Earnings
The report fits under 'Earnings' as it focuses on financial results and future guidance, which provides insights into PRCT's operational efficiency and market potential in the surgical robotics sector.